OTS - CARB-X FUNDS THE 3RD ROUND OF DEBIOPHARM'S TARGETED ANTIBIOTIC PROGRAM TO COMBAT RESISTANT N. GONORRHOEAE INFECTIONS (part 2)
2021. October 19. 09:00
Lausanne, Switzerland, - Boston, USA, 19 October, 2021(APA/OTS) -
About CARB-X
Combating Antibiotic-Resistant Bacteria Biopharmaceutical
Accelerator (CARB-X) is an international not-for-profit partnership
whose mission is to hasten antibacterial research to confront the
worldwide emerging hazard of drug-resistant bacteria. CARB-X
finances the leading scientific innovators across the globe, with
up to $480 million to invest in from 2016 to 2022. Its portfolio
includes the largest preliminary development pipeline of novel
antibiotics, vaccines, rapid diagnostics and other preventative and
diagnostic products in the world. Headquartered at the Boston
University School of Law, the organization is led by Boston
University and is funded by the US Department of Health and Human
Services Biomedical Advanced Research and Development Authority
(BARDA), a branch of the Office of the Assistant Secretary for
Preparedness and Response, the Wellcome Trust, Germany's Federal
Ministry of Education and Research (BMBF), the UK Government's
Global Antimicrobial Resistance Innovation Fund (UK GAMRIF), the
Bill & Melinda Gates Foundation, and receives in-kind support from
National Institute of Allergy and Infectious Diseases (NIAID), part
of the US National Institutes of Health (NIH).
Debiopharm's commitment to patients
Debiopharm develops & manufactures innovative therapies and
drug delivery technologies that target high unmet medical needs in
oncology and infectious diseases. Bridging the gap between
disruptive discovery products and real-world patient reach, we
identify high-potential compounds and technologies for
in-licensing, clinically demonstrate their safety and efficacy and
then select large pharmaceutical commercialization partners to
maximize patient access globally.
For more information, please visit www.debiopharm.com
Follow us on Twitter @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Bonine
Communication Manager
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
(1.) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452490/
(2.) https://www.cdc.gov/std/gonorrhea/arg/default.htm
(3.)
https://www.who.int/news/item/07-07-2017-antibiotic-resistant-gonorrhoea-on-the-rise-new-drugs-neede
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.